Gujarat Kidney & Super Speciality IPO Listing at 6% Premium at ₹120 Per Share

Posted by : sachet | Tue Dec 30 2025

Gujarat Kidney & Super Speciality IPO listing: The Gujarat Kidney & Super Speciality IPO was subscribed 5.21 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.06 times, and non-institutional investors (NIIs) received 5.73 times. The retail quota of the issue was subscribed to 10.00%. Before delving deeper into the topic, go through the details of the Gujarat Kidney & Super Speciality IPO.

Table of Contents

Gujarat Kidney & Super Speciality IPO

It is a bookbuilding IPO of ₹250.80 crore, an entirely fresh issue of 2.20 crore shares. The issue will be listed on BSE and NSE on its tentative listing date, 30th December 2025. The Gujarat Kidney & Super Speciality IPO date is fixed between 22nd December 2025 and 24th December 2025. The face value of Gujarat Kidney & Super Speciality shares stands at ₹2 per share, and the IPO Issue price band is set at ₹108 to ₹114 per share

IPO Allotment Date	26th December 2025
IPO Open Date	22nd December 2025
IPO Close Date	24th December 2025
Refund Initiation	29th December 2025
Issue Size	2,20,00,000 shares(agg. up to ₹250.80 Cr)
Face Value	₹2 per share
Lot Size	128 Shares
Issue Price	₹108 to ₹114 per share
Issue Type	Bookbuilding IPO
Listing At	BSE NSE
Listing Date	30th December 2025

Gujarat Kidney & Super Speciality IPO Listing

On the NSE platforms, Gujarat Kidney & Super Speciality shares are listed at ₹120 per share, reflecting a 5.26% premium to the issue price of ₹114 per share. On the other hand, on the BSE platform, shares are listed at ₹120.75 per share, reflecting a premium of 5.92% from their issue price of ₹114 per share.

About the Gujarat Kidney & Super Speciality IPO

Gujarat Kidney & Super Speciality was established in 2019. Gujarat Kidney and Super Speciality Limited (GKASSL) specialises in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India. The company operates seven multispeciality hospitals and four pharmacies, with a total bed capacity of 490, an approved capacity of 455, and an operational capacity of 340. The company’s hospitals include Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), and Ashwini Medical Centre (Anand). The company also operates Ashwini Medical Store (Anand).

Gujarat Kidney & Super Speciality Limited Financials

The company’s financial analysis is essential before applying for Gujarat Kidney & Super Speciality Limited’s IPO. Refer to the table to learn about Vidya Wires Limited’s financial information.

Year Ended	30th June 2025 (in cr.)	31st March 2025 (in cr.)	31st March 2024	31st March 2023
Assets	61.59	55.34	20.53	3.87
Revenue	15.27	40.40	5.48	0.00
Profit After Tax	5.40	9.50	1.71	-0.01
EBITDA	8.63	16.55	1.95	-0.01
Net Worth	30.56	25.71	10.80	0.37
Reserves and Surplus	19.42	14.57	10.60	0.17
Total Borrowings	4.03	3.88	1.94	–

Explanation

Gujarat Kidney & Super Speciality Limited’s revenue increased by 637% from ₹5.48 crores in March 2024 to ₹40.40 crores in March 2025. Moreover, the company’s PAT increased by 454% from ₹1.71 crores in March 2024 to ₹9.50 crores in March 2025.